Background Malignant pleural mesothelioma (MPM) is an aggressive cancer of the cells
lining the pleural cavity with a low overall incidence. The National Cancer Database (NCDB) …

Background The definition of hyperprogressive disease (HPD) is controversial in the
literature and has not been widely described in melanoma. The aim of this study was to …

Background Immune checkpoint blockade (ICB) elicits a strong and durable therapeutic
response, but its application is limited by disparate responses and its associated immune …

Immune checkpoint inhibitors are increasingly used in combination with chemotherapy for
the treatment of non-small cell lung cancer, yet the success of combination therapies is …

This study aimed to develop a computed tomography (CT)-based radiomics model capable
of precisely predicting hyperprogression and pseudoprogression (PP) in patients with non …

Atezolizumab plus bevacizumab treatment for unresectable hep... : Medicine Atezolizumab
plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after …

Introduction Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC
are difficult to extrapolate to real-world practice given the exclusion of patients with poor …

Background For decades, stratification criteria for first-line clinical studies have been highly
uniform. However, there is no principle or consensus for restratification after systemic …

The choice of first-line palliative treatment has always been one of the crucial decisions in
the management of patients with recurrent and/or metastatic squamous cell carcinoma of the …

Significant advances in the detection and treatment of initial cancers increase the likelihood
of life-threatening subsequent primary cancers, particularly for long-term survivors. A brief …